Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-07
2006-11-07
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S303000, C544S262000, C546S119000
Reexamination Certificate
active
07132426
ABSTRACT:
The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism.Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
REFERENCES:
patent: 4139705 (1979-02-01), Dunbar et al.
patent: 4189579 (1980-02-01), Dunbar et al.
patent: 4343804 (1982-08-01), Munison et al.
patent: 5952504 (1999-09-01), Yoo et al.
patent: 6060478 (2000-05-01), Gilligan
patent: 6107301 (2000-08-01), Aldrich et al.
patent: 6350750 (2002-02-01), Den Hartog et al.
patent: 6506762 (2003-01-01), Horvath et al.
patent: 6552192 (2003-04-01), Hanus et al.
patent: 1040831 (2000-10-01), None
patent: 1097709 (2001-05-01), None
patent: 1340749 (2003-09-01), None
patent: 1475094 (2004-11-01), None
patent: 61 057587 (1986-03-01), None
patent: 2000-038350 (2000-02-01), None
patent: 2004-269468 (2004-09-01), None
patent: 2004-269469 (2004-09-01), None
patent: WO 94/13677 (1994-06-01), None
patent: WO 96/35689 (1996-11-01), None
patent: WO 97/29109 (1997-08-01), None
patent: WO 97/49706 (1997-12-01), None
patent: WO 98/08846 (1998-03-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 98/35967 (1998-08-01), None
patent: WO 98/47874 (1998-10-01), None
patent: WO 98/47903 (1998-10-01), None
patent: WO 99/51599 (1999-10-01), None
patent: WO 2000/11003 (2000-03-01), None
patent: WO 01/23387 (2001-04-01), None
patent: WO 01/23388 (2001-04-01), None
patent: WO 01/053263 (2001-07-01), None
patent: WO 01/087892 (2001-11-01), None
patent: WO 02/02549 (2002-01-01), None
patent: WO 2002/19975 (2002-03-01), None
patent: WO 02/40456 (2002-05-01), None
patent: WO 02/40458 (2002-05-01), None
patent: WO 02/040480 (2002-05-01), None
patent: WO 03/026661 (2002-09-01), None
patent: WO 2002/072101 (2002-09-01), None
patent: WO 02/098878 (2002-12-01), None
patent: WO 03/000666 (2003-01-01), None
patent: WO 03/032989 (2003-04-01), None
patent: WO 04/000843 (2003-12-01), None
patent: WO 2004/000843 (2003-12-01), None
patent: WO 2004/009596 (2004-01-01), None
patent: WO 2004/009597 (2004-01-01), None
patent: WO 2004/009602 (2004-01-01), None
patent: WO 2004/013633 (2004-02-01), None
patent: WO 2004/035588 (2004-04-01), None
patent: WO 2004/062665 (2004-07-01), None
patent: WO 05/061489 (2005-07-01), None
Cheng, et al. Potential Purine Antagonist. VI. Synthesis of 1-Alkyl and 1-Aryl-4-Substituted Pyrazolo[3,4-d]pyrimidines, J. Org. Chem., vol. 21, pp. 1240-1256 (1956).
Huang et al., “Synthesis and antiplatelet activity of phenyl quinolones,”Bioorganic&Medicinal Chemistry(1998) 6:1657-1662.
Chan et al., “Isoquinoline-6-carboxamides as potent and selective anti-human cytomegalovirus (HCMV) inhibitors,”Bioorganic&Medicinal Chemistry Letter(1999) 9:2583-2586.
Jia et al., “Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides,”Bioorganic&Medicinal Chemistry Letters(2002) 12:1651-1655.
Chen et al., “Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility,”Bioorganic&Medicinal Chemistry Letters(2004) 14:3669-3673.
Cocuzza et al., “Use of the Suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists,”Bioorganic&Medicinal Chemistry Letters(1999) 9:1063-1066.
Quintela et al., “6-Dimethylamino 1H-pyrazolo[3,4-d]pyrimidine derivatives as new inhibitors of inflammatory mediators in intact cells,”Bioorganic&Medicinal Chemistry Letters(2003) 11:863-868.
Accession No. 2003:2415108 Chemcats, 1H-Pyrazolo [3,4-d] pyrimidin-4-amine, N-cyclohexyl-N-methyl-1-(3-methylphenyl)-, 2004 14:39-58.
Accession No. 2003:2415906 Chemcats, 1H-Pyrazolo [3,4-d] pyrimidin-4-amine, N-cyclohexyl-1-(4-methoxyphenyl)-N-methyl-, 2004 14:39:48.
Accession No. 2003:2416398 Chemcats, 1H-Pyrazolo [3,4-d]pyrimidin-4-amine, N-cyclohexyl-1-(2,4-dimethylphenyl)-N-methyl-, 2004 14:39:37.
Accession No. 2003:2417080 Chemcats, 1H-Pyrazolo [3,4-d]pyrimidin-4-amine, N-cyclohexyl-N-methyl-1-phenyl-, 2004 14:39:27.
Gilligan et al., “Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases,”Current Opinion in Drug Discovery&Development(2004) 7(4):487-497.
Quintela et al., “Pyrazolopyrimidines: synthesis, effect on histamine release from rat peritoneal mast cells and cytotoxic activity,”Eur. J. Med. Chem. (2001) 36:321-332.
Lanier et al., “Small molecule corticotrophin-releasing factor antanonists,”Expert Opin. Ther. Patents. (2002) 12(11):1619-1630.
Nesi et al., “New difunctionalized 4-nitroisoxazoles from alpha-nitroacetophenone oxime,”Heterocycles(1985) 23(6):1465-1469.
Miyashita et al., “Preparation of heteroarenecarbonitriles by reaction of haloheteroarenes with potassium cyanide catalyzed by sodiump-toluenesulfinate,”Heterocycles(1994) 39(1):345-350.
Robins et al., “Potential purine antagonists. IV. Syntheis of some 9-methyl-6-substituted-purines,”Department of Chemistry, New Mexico Highlands University(1956) 79:490-494.
Baindur et al., “Solution-phase synthesis of a library of 3,5,7-trisubstituted 3H-[1,2,3]triazolo[4,5-d]pyrimidines,”J. Comb. Chem. (2003) 5:653-659.
He et al., “4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist,”J. Med. Chem. (2000) 43:449-456.
Giner-Sorolla et al., “The synthesis and properties of 6-mercaptomethylpurine and derivatives,”Division of Nucleoprotein Chemistry, Sloan-Kettering Institute for Cancer Research(1965) 8:667-672.
Meuller et al., “7-Deaza-2-phenyladenines: structure-activity relationships of potent A1 selective adenosine receptor antagonists,”J. Med. Chem. (1990) 33:2822-2828.
Thompson et al., “N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor,”J. Med. Chem. (1991) 34:2877-2882.
Press et al., “Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes,”J. of Medicinal Chemistry(1992) 35(24):4509-4515.
Rewcastle et al., “Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor,”J. Med. Chem. (1996) 39(9):1823-1835.
Chen et al., “Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists,”J. Med. Chem. (1996) 39-4358-4360.
Betti et al., “Novel 3-aralkyl-7-(amino-substituted)-1,2,3-triazolo[4,5-d]pyrimidines with high affinity toward A1 adenosine receptors,”J. Med. Chem. (1998) 41(5):668-673.
Chorvat et al., “Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines,”J. Med. Chem. (1999) 42(5):833-848.
Gilligan et al., “Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents,”Journal of Medicinal Chemistry(2000) 43(9):1641-1660.
Hersperger et al. “Palladium-catalyzed cross-coupling reactions for the synthesis of 6,8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors,”J. Med. Chem. (2000) 43:675-682.
Gomtsyan et al. “Design, synthesis, and structure-activity relationship of 6-alkynylpyrimidines as potent adenosine kinase inhibitors,”J. Med. Chem. (2002) 45:3639-3648.
Cohen et al., “The preparation and properties of 6-halomethylpurines,”Division
Calderon Imelda
Choi Jin Sun Karoline
Fioravanti Beatriz
Jones Robert M.
Ren Albert S.
Arena Pharmaceuticals Inc.
Goddard Christine A.
Grazier Nyeemah
O'Connor Cozen
Saeed Kamal A.
LandOfFree
Fused-aryl and heteroaryl derivatives as modulators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused-aryl and heteroaryl derivatives as modulators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused-aryl and heteroaryl derivatives as modulators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3652361